uploads/2018/10/Chart-002-2-1.jpg

How Did Pharmaceutical ETFs Perform in Q3 2018?

By

Updated

Pharmaceuticals ETFs

In this article, we’ll discuss several major ETFs in the pharmaceuticals sector and their third-quarter returns. The chart below compares the market capitalization of these pharmaceutical ETFs on October 3.

Article continues below advertisement

The Healthcare Select Sector SPDR ETF

The Healthcare Select Sector SPDR ETF (XLV) focuses on pharmaceutical and biotechnology companies. This fund has been operational since 1998, and its market capitalization was $18.3 billion on October 2. XLV’s price has increased ~14.6% in the third quarter, and its YTD (year-to-date) returns increased ~15.5% on October 2.

The VanEck Vectors Pharmaceuticals ETF

The VanEck Vectors Pharmaceuticals ETF (PPH) focuses on large drug manufacturing companies. This fund has been operational since 2011, and its market capitalization was $288.7 million on October 2. PPH’s price has increased ~8.6% in the third quarter, and its YTD returns increased ~7.9% on October 2.

Article continues below advertisement

The iShares US Pharmaceuticals ETF

The iShares US Pharmaceuticals ETF (IHE) focuses on large drug manufacturing companies. IHE was launched in 2006, and its market capitalization was $440.4 million on October 2. IHE’s price increased ~9.6% in the third quarter, and its YTD returns increased ~7.3% on October 2.

The Invesco Dynamic Pharmaceuticals ETF

The Invesco Dynamic Pharmaceuticals ETF (PJP) focuses on drug manufacturers and biotechnology companies. This fund has been operational since 2005, and its market capitalization was $587.2 million on October 2. PJP’s price increased ~7.8% in the third quarter, and its year-to-date returns increased ~12.9% on October 2.

The SPDR S&P Pharmaceuticals ETF

The SPDR S&P Pharmaceuticals ETF (XPH) focuses on drug manufacturers and biotechnology companies. This fund tracks an index that represents the pharmaceutical subindustry portion of the S&P Total Markets Index.

XPH has operational since 2006, and its market capitalization was ~$396.9 million on October 2. XPH’s price has increased ~9.0% in the third quarter, and its YTD returns increased 8.0% on October 2.

The Invesco Dynamic Pharmaceuticals ETF (PJP) holds 5.4% in Pfizer (PFE), 5.2% in Bristol-Myers Squibb (BMY), 5.2% in Amgen (AMGN), and 5.0% in AbbVie (ABBV).

Advertisement

More From Market Realist